Company intelligence / Profile preview

Aqua Bio Technology

Oslo, Oslo, Norway

Ownership: Private
Employees: ~37
Development stage: Other

Overview

ABT has developed and commercialized proprietary natural ingredients—including Aquabeautine XL™, now licensed to US skincare companies; company markets ingredients and third-party natural skincare products throughout EMEA. No clinical trial data as products are cosmetics, not drugs

Therapeutic areas: Dermatology
Modalities: ProteinEnzymeExtract
Industry: Non-Drug Biotech

Partnerships

DCP Dermoscience (Canada) joint venture (2020)US-based companies licensed Aquabeautine XL™ (since 2012)EMEA manufacturing/marketing rights for third-party natural skincare product lines

Beyond the preview

Go deeper on Aqua Bio Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aqua Bio Technology.

Explore the full profile